5.43k followers • 18 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Bristol-Myers Squibb Company
Seattle Genetics, Inc.
Exact Sciences Corporation
Blueprint Medicines Corporation
Genomic Health, Inc.
Spectrum Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc.
Foundation Medicine, Inc.
Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
The company said the trial will continue unchanged as per the recommendation of a data monitoring committee. The trial was testing Bristol-Myers' drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma. The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year.
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inovio (INO) delivered earnings and revenue surprises of 0.00% and -68.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.
Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.
FibroGen (FGEN) delivered earnings and revenue surprises of 3.39% and 8.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.